Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hepatitis HELP
Based on 45,776 articles since 2008
||||

These are the 45776 published articles about Hepatitis that originated from Worldwide during 2008-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC): summary of conclusions and recommendations, 1–2 February 2017 meeting. 2017

Anonymous2461115. · ·Wkly Epidemiol Rec · Pubmed #28413874.

ABSTRACT: -- No abstract --

2 Guideline Practice Alert: ACIP vaccine update, 2017. 2017

Campos-Outcalt, Doug. ·Medical Director, Mercy Care Plan, Phoenix, AZ, USA. Email:campos-outcaltd@mercycareplan.com. ·J Fam Pract · Pubmed #28249054.

ABSTRACT: HIV infection is now an indication for meningococcus vaccination and HPV vaccine dosing is simpler for patients ⟨15 years.

3 Guideline  Joint Society statement for elimination of viral hepatitis. 2017

Brahm, Javier / Castera, Laurent / Hou, Jinlin / Lindor, Keith. ·Latin American Association for the Study of the Liver. · European Association of the Study of the Liver. · Asian Pacific Association for the Study of the Liver. · American Association for the Study of Liver Disease. ·Ann Hepatol · Pubmed #28051786.

ABSTRACT: -- No abstract --

4 Guideline [Management following sexual exposure to HIV, HVB and HVC]. 2016

Timsit, F-J / Vernay-Vaisse, C / Derancourt, C / Viraben, R / Chartier, C / Spenatto, N / Anonymous3261106. ·Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. Electronic address: centre.mst@aphp.fr. · CIDAG/CIDDIST MDS Aubagne, 10, allée Antide-Boyer, 13400 Aubagne, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort de France, France. · Service de dermatologie et médecine sociale, pôle santé publique et médecine sociale, hôpital La Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · 24, place Kléber, 67000 Strasbourg, France. · ·Ann Dermatol Venereol · Pubmed #27776810.

ABSTRACT: -- No abstract --

5 Guideline [STD and STI screening]. 2016

Vernay-Vaïsse, C / Spenatto, N / Derancourt, C / Timsit, F-J / Fouéré, S / Pinault, A-L / Anonymous3121106. ·CIDAG/CIDDIST CD 13, DPMISP, 4, quai d'Arenc, CS 70095, 13304 Marseille cedex 02, France. Electronic address: chantal.vernayvaisse@cg13.fr. · Pôle santé publique et médecine sociale, service de dermatologie et médecine sociale, hôpital La-Grave, place Lange, TSA 60033, 31059 Toulouse cedex 9, France. · Service de dermatologie, CHU de Fort-de-France, 97261 Fort-de-France, Martinique. · Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 Paris, France. · 41, boulevard Henri IV, 75004 Paris, France. · Service de dermatologie, hôpital de Brabois, CHU de Nancy, 5, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. · ·Ann Dermatol Venereol · Pubmed #27773502.

ABSTRACT: -- No abstract --

6 Guideline SASLT guidelines: Update in treatment of Hepatitis C virus infection. 2016

Alghamdi, Abdullah S / Alghamdi, Mohammed / Sanai, Faisal M / Alghamdi, Hamdan / Aba-Alkhail, Faisal / Alswat, Khalid / Babatin, Mohammed / Alqutub, Adel / Altraif, Ibrahim / Alfaleh, Faleh. ·Department of Medicine, Gastroenterology Unit, King Fahad Hospital, Jeddah, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Fahd Military Complex, Dhahran, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia. · Department of Hepatobiliary Sciences and Liver Transplantation King Abdulaziz Medical City, and King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia. · Department of Medicine, Division of Gastroenterology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. · Department of Medicine, Gastroenterology unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia. · Department of Medical Specialties, Gastroenterology and Hepatology Section, King Fahad Medical City, Riyadh, Saudi Arabia. ·Saudi J Gastroenterol · Pubmed #27538727.

ABSTRACT: -- No abstract --

7 Guideline KASL clinical practice guidelines: management of hepatitis C. 2016

Anonymous360951. · ·Clin Mol Hepatol · Pubmed #27044763.

ABSTRACT: -- No abstract --

8 Guideline KASL clinical practice guidelines: management of chronic hepatitis B. 2016

Anonymous350951. · ·Clin Mol Hepatol · Pubmed #27044762.

ABSTRACT: -- No abstract --

9 Guideline Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. 2016

Crabb, David W / Bataller, Ramon / Chalasani, Naga P / Kamath, Patrick S / Lucey, Michael / Mathurin, Philippe / McClain, Craig / McCullough, Arthur / Mitchell, Mack C / Morgan, Timothy R / Nagy, Laura / Radaeva, Svetlana / Sanyal, Arun / Shah, Vijay / Szabo, Gyongyi / Anonymous251086. ·Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, School of Medicine, Indianapolis, Indiana. Electronic address: dcrabb@iu.edu. · Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. · Division of Gastroenterology and Hepatology Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. · Gastroenterology Research Unit, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. · Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin, Madison, Wisconsin. · Service Maladie de l'Appareil Digestif and INSERM U995 Univ Lille 2, CHRU Lille, France. · Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky. · Departments of Gastroenterology, Hepatology and Transplant Surgery, Cleveland Clinic, Cleveland, Ohio. · Division of Digestive and Liver Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas. · VA Long Beach Healthcare System, Long Beach, California. · Department of Pathobiology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. · Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. · Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, Virginia. · Division of Gastroenterology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts. · ·Gastroenterology · Pubmed #26921783.

ABSTRACT: -- No abstract --

10 Guideline ACG Clinical Guideline: Liver Disease and Pregnancy. 2016

Tran, Tram T / Ahn, Joseph / Reau, Nancy S. ·Department of Medicine, Liver Transplant, Cedars Sinai Medical Center, Los Angeles, California, USA. · Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA. · Department of Medicine, Rush University, Chicago, Illinois, USA. ·Am J Gastroenterol · Pubmed #26832651.

ABSTRACT: Consultation for liver disease in pregnant women is a common and oftentimes vexing clinical consultation for the gastroenterologist. The challenge lies in the need to consider the safety of both the expectant mother and the unborn fetus in the clinical management decisions. This practice guideline provides an evidence-based approach to common diagnostic and treatment challenges of liver disease in pregnant women.

11 Guideline AISF position paper on liver disease and pregnancy. 2016

Anonymous380947 / Anonymous390947. · ·Dig Liver Dis · Pubmed #26747754.

ABSTRACT: The relationship between liver disease and pregnancy is of great clinical impact. Severe liver disease in pregnancy is rare; however, pregnancy-related liver disease is the most frequent cause of liver dysfunction during pregnancy and represents a severe threat to foetal and maternal survival. A rapid differential diagnosis between liver disease related or unrelated to pregnancy is required in women who present with liver dysfunction during pregnancy. This report summarizes the recommendation of an expert panel established by the Italian Association for the Study of the Liver (AISF) on the management of liver disease during pregnancy. The article provides an overview of liver disease occurring in pregnancy, an update on the key mechanisms involved in its pathogenesis, and an assessment of the available treatment options. The report contains in three sections: (1) specific liver diseases of pregnancy; (2) liver disease occurring during pregnancy; and (3) pregnancy in patients with pre-existing chronic liver disease. Each topic is discussed considering the most relevant data available in literature; the final statements are formulated according to both scientific evidence and clinical expertise of the involved physicians, and the AISF expert panel recommendations are reported.

12 Guideline Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. 2016

Sarin, S K / Kumar, M / Lau, G K / Abbas, Z / Chan, H L Y / Chen, C J / Chen, D S / Chen, H L / Chen, P J / Chien, R N / Dokmeci, A K / Gane, Ed / Hou, J L / Jafri, W / Jia, J / Kim, J H / Lai, C L / Lee, H C / Lim, S G / Liu, C J / Locarnini, S / Al Mahtab, M / Mohamed, R / Omata, M / Park, J / Piratvisuth, T / Sharma, B C / Sollano, J / Wang, F S / Wei, L / Yuen, M F / Zheng, S S / Kao, J H. ·Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. shivsarin@gmail.com. · Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. · Division of Gastroenterology and Hepatology, Humanity and Health Medical Centre, Hong Kong SAR, China.; The Institute of Translational Hepatology, Beijing, China. · Department of Hepatogastroenterlogy, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. · Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. · Genomics Research Center, Academia Sinica, National Taiwan University, Taipei, Taiwan. · Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. · Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. · Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. · Liver Research Unit, Chang Gung Memorial Hospital and University, Chilung, Taiwan. · Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. · New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand. · Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Guangzhou, China. · Department of Medicine, Aga Khan University, Karachi, Pakistan. · Beijing Friendship Hospital, Capital Medical University, Beijing, China. · , Seoul, Korea. · Department of Medicine, University of Hong Kong, Hong Kong, China. · Internal Medicine Asan Medical Center, Seoul, Korea. · Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore. · Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia. · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. · Department of Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. · Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. · Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. · NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Songkhla, Thailand. · Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. · Department of Medicine, University of Santo Tomas, Manila, Philippines. · Treatment and Research Center for Infectious Diseases, Beijing 302 Hospital, Beijing, China. · Peking University Hepatology Institute, Beijing, China. · Division of Gastroenterology and Hepatology, Department of Medicine, University of Hong Kong, Pofulam, Hong Kong. · Department of Hepatobiliary and Pancreatic Surgery, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China. · Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine, National Taiwan University Hospital, Taipei, Taiwan. ·Hepatol Int · Pubmed #26563120.

ABSTRACT: Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts' personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

13 Guideline HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. 2016

Reau, Nancy / Fried, Michael W / Nelson, David R / Brown, Robert S / Everson, Gregory T / Gordon, Stuart C / Jacobson, Ira M / Lim, Joseph K / Pockros, Paul J / Reddy, K Rajender / Sherman, Kenneth E. ·Rush University Medical Center, Chicago, IL, USA. · University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. · University of Florida, Gainesville, FL, USA. · Weill Cornell Medical College, New York, NY, USA. · University of Colorado, Aurora, CO, USA. · Henry Ford Medical Center, Detroit, MI, USA. · Yale University School of Medicine, New Haven, CT, USA. · Scripps Translational Science Institute, La Jolla, CA, USA. · University of Pennsylvania, Philadelphia, PA, USA. · University of Cincinnati College of Medicine, Cincinnati, OH, USA. ·Liver Int · Pubmed #26509462.

ABSTRACT: BACKGROUND & AIMS: HCV Council 2014, like its predecessor HCV Council 2011, assembled leading clinicians and researchers in the field of hepatitis C to critically evaluate current data regarding best practices for managing patients with chronic hepatitis C virus (HCV). METHODS: Clinical practice statements were developed that reflect the areas of potential controversy with high clinical impact. Faculty members were responsible for reviewing the literature to support or reject these statements. After a review and comprehensive discussion of the data, the HCV Council faculty voted on the nature of the evidence and the level of support for each statement. RESULTS: The results of the detailed analysis with expert opinion are summarized in this article. CONCLUSION: Numerous questions regarding optimal management of certain populations and clinical scenarios remain unanswered. The discussion in the article provides a summary of evidenced-based expert opinion that may help guide clinicians as additional information is developed.

14 Guideline Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. 2015

Bittencourt, Paulo Lisboa / Cançado, Eduardo Luiz Rachid / Couto, Cláudia Alves / Levy, Cynthia / Porta, Gilda / Silva, Antônio Eduardo Benedito / Terrabuio, Debora Raquel Benedita / Anonymous4170861 / Carvalho Filho, Roberto José de / Chaves, Dalton Marques / Miura, Irene Kazue / Codes, Liana / Faria, Luciana Costa / Evangelista, Andreia Silva / Farias, Alberto Queiroz / Gonçalves, Luciana Lofêgo / Harriz, Michele / Lopes Neto, Edmundo Pessoa A / Luz, Gustavo Oliveira / Oliveira, Patrícia / Oliveira, Elze Maria Gomes de / Schiavon, Janaina Luz Narciso / Seva-Pereira, Tiago / Parise, Edison Roberto. ·Hospital Português, Salvador, BA, Brazil. · Faculdade de Medicina, Universidade de São Paulo, SP, Brazil. · Faculdade de Medicina, Universidade Federal de Minas Gerais, MG, Brazil. · University of Miami, USA. · Faculdade de Medicina, Universidade Federal de São Paulo, SP, Brazil. · · Hospital Israelita Albert Einstein, SP, Brazil. · Universidade Federal do Espírito Santo, Vitória, ES, Brazil. · Hospital Universitário, Faculdade de Medicina, Universidade Federal de Espírito Santo, ES, Brazil. ·Arq Gastroenterol · Pubmed #26959804.

ABSTRACT: In order to draw evidence-based recommendations concerning the management of autoimmune diseases of the liver, the Brazilian Society of Hepatology has sponsored a single-topic meeting in October 18th, 2014 at São Paulo. An organizing committee comprised of seven investigators was previously elected by the Governing Board to organize the scientific agenda as well as to select twenty panelists to make a systematic review of the literature and to present topics related to the diagnosis and treatment of autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and their overlap syndromes. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of those recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present paper is the final version of the reviewed manuscript organized in topics, followed by the recommendations of the Brazilian Society of Hepatology.

15 Guideline Recommendations for the treatment of hepatitis C Polish group of HCV Experts--2015. 2015

Halota, Waldemar / Flisiak, Robert / Boroń-Kaczmarska, Anna / Juszczyk, Jacek / Pawłowska, Małgorzata / Simon, Krzysztof / Tomasiewicz, Krzysztof / Małkowski, Piotr / Anonymous8790847. · ·Przegl Epidemiol · Pubmed #26519849.

ABSTRACT: -- No abstract --

16 Guideline EASL Clinical Practice Guidelines: Autoimmune hepatitis. 2015

Anonymous2480971. ·EASL office, 7 Rue Daubin, CH 1203 Geneva, Switzerland, email: easloffice@easloffice.eu ·J Hepatol · Pubmed #26341719.

ABSTRACT: -- No abstract --

17 Guideline Recommendations for the management of hepatitis C virus infection among people who inject drugs. 2015

Grebely, Jason / Robaeys, Geert / Bruggmann, Philip / Aghemo, Alessio / Backmund, Markus / Bruneau, Julie / Byrne, Jude / Dalgard, Olav / Feld, Jordan J / Hellard, Margaret / Hickman, Matthew / Kautz, Achim / Litwin, Alain / Lloyd, Andrew R / Mauss, Stefan / Prins, Maria / Swan, Tracy / Schaefer, Martin / Taylor, Lynn E / Dore, Gregory J / Anonymous11701089. ·Kirby Institute, UNSW Australia, Sydney, Australia. Electronic address: jgrebely@kirby.unsw.edu.au. · Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium; Department of Hepatology, UZ Leuven, Leuven, Belgium; Faculty of Medicine and Life Sciences, Limburg Clinical Research Program, Hasselt University, Hasselt, Belgium. · Arud Centres of Addiction Medicine, Zurich, Switzerland. · A.M. Migliavacca Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy. · Ludwig-Maximilians-University, Munich, Germany; Praxiszentrum im Tal Munich, Munich, Germany. · CRCHUM, Université de Montréal, Montreal, Canada. · International Network of People who Use Drugs, Canberra, Australia. · Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway. · University of Toronto, Toronto, Canada. · Burnet Institute, Melbourne, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. · School of Social & Community Medicine, University of Bristol, Bristol, United Kingdom. · European Liver Patients Association, Cologne, Germany. · Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States. · Inflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, Australia. · Center for HIV and Hepatogastroenterology, Düsseldorf, Germany. · Department of Research, Cluster Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine, CINIMA, Academic Medical Centre, Amsterdam, The Netherlands. · Treatment Action Group, New York, United States. · Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, Essen, Germany; Department of Psychiatry and Psychotherapy-CCM, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Department of Medicine, Brown University, Providence, RI, United States. · Kirby Institute, UNSW Australia, Sydney, Australia. · ·Int J Drug Policy · Pubmed #26282715.

ABSTRACT: In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and care. Further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWID, particularly as new interferon-free DAA treatments for HCV infection become available.

18 Guideline Sexually transmitted diseases treatment guidelines, 2015. 2015

Workowski, Kimberly A / Bolan, Gail A / Anonymous5930832. · ·MMWR Recomm Rep · Pubmed #26042815.

ABSTRACT: These guidelines for the treatment of persons who have or are at risk for sexually transmitted diseases (STDs) were updated by CDC after consultation with a group of professionals knowledgeable in the field of STDs who met in Atlanta on April 30-May 2, 2013. The information in this report updates the Sexually Transmitted Diseases Treatment Guidelines, 2010 (MMWR Recomm Rep 2010;59 [No. RR-12]). These updated guidelines discuss 1) alternative treatment regimens for Neisseria gonorrhoeae; 2) the use of nucleic acid amplification tests for the diagnosis of trichomoniasis; 3) alternative treatment options for genital warts; 4) the role of Mycoplasma genitalium in urethritis/cervicitis and treatment-related implications; 5) updated HPV vaccine recommendations and counseling messages; 6) the management of persons who are transgender; 7) annual testing for hepatitis C in persons with HIV infection; 8) updated recommendations for diagnostic evaluation of urethritis; and 9) retesting to detect repeat infection. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STDs.

19 Guideline Mexican consensus on the diagnosis and management of hepatitis C infection. 2015

Sánchez-Ávila, Juan Francisco / Dehesa-Violante, Margarita / Méndez-Sánchez, Nahum / Bosques-Padilla, Francisco / Castillo-Barradas, Mauricio / Castro-Narro, Graciela / Cisneros-Garza, Laura / Chirino-Sprung, Ruby Ann / García-Juarez, Ignacio / Gonzalez-Huezo, Ma Saraí / Malé-Velazquez, René / Moreno-Alcántar, Rosalba / Muñoz-Espinoza, Linda / Ramos-Gómez, Mayra / Rizo-Robles, Ma Teresa / Sandoval-Salas, Ricardo / Sierra-Madero, Juan / Torres-Ibarra, María Del Rocío / Vazquez-Frias, Rodrigo / Wolpert-Barraza, Enrique / Anonymous6370830 / Anonymous6380830 / Anonymous6390830. ·Department of Gastroenterology, INCMNSZ. Mexican Association of Hepatology. Mexico City, Mexico. · Mexican Association of Hepatology. Mexico City, Mexico. · Liver Research Unit. Medica Sur Clinic & Foundation. Mexico City, Mexico. · C. Facultad de Medicina y Hospital Universitario J.E. González. UANL, Monterrey, Nuevo Leon, Mexico. · Department of Gastroenterology, CMN La Raza, IMSS Mexico City, Mexico. · Department of Gastroenterology, INCMNSZ. Mexico City, Mexico. · Liver Disease Clinic, Hospital San José TEC de Monterrey Monterrey, Nuevo Leon, Mexico. · 8Gastroenterology, Hospital Ángeles, Mexico City, Mexico. · Department of Gastroenterology, INCMNSZ, Mexico City, Mexico. · Department of Gastroenterology, ISSEMYM, Toluca, Estado de Mexico, Mexico. · Instituto de Salud Digestiva y Hepáticas. Department of Gastroenterology, Hospital del Carmen Guadalajara, Jalisco, Mexico. · Department of Gastroenterology, Hospital de Especialidades CMN SXXI, IMSS, Mexico City, Mexico. · Liver Unit, Hospital Universitario J.E. González. UANL Monterrey, Nuevo Leon, Mexico. · Department of Gastroenterology, CMN 20 de Noviembre, ISSSTE,, Mexico City, Mexico. · Department of Gastroenterology, CMN La Raza, IMSS. Mexican Association of Hepatology, Mexico City, Mexico. · Department of Gastroenterology, Hospital de Especialidades, CMN Siglo XXI, IMSS, Mexico City, Mexico. · Department of Infectious Disease, INCMNSZ, Mexico City, Mexico. · Department of Infectious Disease, Hospital de Infectología, CMN La Raza, IMSS, Mexico City, Mexico. · Department of Gastroenterology, Hospital Infantil de México "Federico Gómez", SSA, Mexico City, Mexico. · Clínica Lomas Altas. Mexican Association of Gastroenterology. Mexico City, Mexico. · ·Ann Hepatol · Pubmed #25983318.

ABSTRACT: -- No abstract --

20 Guideline [Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. 2015

Wedemeyer, Heiner / Zeuzem, Stefan / Manns, Michael P / Anonymous5780825 / Anonymous5790825. · ·Z Gastroenterol · Pubmed #25821867.

ABSTRACT: -- No abstract --

21 Guideline Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. 2015

Huprikar, S / Danziger-Isakov, L / Ahn, J / Naugler, S / Blumberg, E / Avery, R K / Koval, C / Lease, E D / Pillai, A / Doucette, K E / Levitsky, J / Morris, M I / Lu, K / McDermott, J K / Mone, T / Orlowski, J P / Dadhania, D M / Abbott, K / Horslen, S / Laskin, B L / Mougdil, A / Venkat, V L / Korenblat, K / Kumar, V / Grossi, P / Bloom, R D / Brown, K / Kotton, C N / Kumar, D. ·Icahn School of Medicine at Mount Sinai, New York, NY. · ·Am J Transplant · Pubmed #25707744.

ABSTRACT: Use of organs from donors testing positive for hepatitis B virus (HBV) may safely expand the donor pool. The American Society of Transplantation convened a multidisciplinary expert panel that reviewed the existing literature and developed consensus recommendations for recipient management following the use of organs from HBV positive donors. Transmission risk is highest with liver donors and significantly lower with non-liver (kidney and thoracic) donors. Antiviral prophylaxis significantly reduces the rate of transmission to liver recipients from isolated HBV core antibody positive (anti-HBc+) donors. Organs from anti-HBc+ donors should be considered for all adult transplant candidates after an individualized assessment of the risks and benefits and appropriate patient consent. Indefinite antiviral prophylaxis is recommended in liver recipients with no immunity or vaccine immunity but not in liver recipients with natural immunity. Antiviral prophylaxis may be considered for up to 1 year in susceptible non-liver recipients but is not recommended in immune non-liver recipients. Although no longer the treatment of choice in patients with chronic HBV, lamivudine remains the most cost-effective choice for prophylaxis in this setting. Hepatitis B immunoglobulin is not recommended.

22 Guideline [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. 2015

Hunyady, Béla / Gerlei, Zsuzsanna / Gervain, Judit / Horváth, Gábor / Lengyel, Gabriella / Pár, Alajos / Rókusz, László / Szalay, Ferenc / Telegdy, László / Tornai, István / Werling, Klára / Makara, Mihály. ·Somogy Megyei Kaposi Mór Oktató Kórház Belgyógyászati Osztály Kaposvár Tallián Gy. u. 20-32. 7400 Pécsi Tudományegyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Pécs. · Semmelweis Egyetem, Általános Orvostudományi Kar Transzplantációs és Sebészeti Klinika Budapest. · Szent György Egyetemi Oktató Kórház I. Belgyógyászat és Molekuláris Diagnosztikai Laboratórium Székesfehérvár. · Szent János Kórház és Észak-budai Egyesített Kórházak Hepatológiai Szakrendelés Budapest. · Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest. · Pécsi Tudományegyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Pécs. · MH Egészségügyi Központ Honvédkórház I. Belgyógyászati Osztály Budapest. · Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest. · Egyesített Szent István és Szent László Kórház Budapest. · Debreceni Egyetem, Általános Orvostudományi Kar, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet Debrecen. ·Orv Hetil · Pubmed #25702254.

ABSTRACT: Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. Furthermore, these could from prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity, as a socioeconomic aspect. Pegylated interferon + ribavirin dual therapy, which is available in Hungary since 2003, can clear the virus in 40-45% of previously not treated (naïve), and in 5-21% of previous treatment-failure patients. Addition of a direct acting first generation protease inhibitor drug (boceprevir or telaprevir) to the dual therapy increases the chance of sustained viral response to 63-75% and 59-66%, respectively. These two protease inhibitors are available and financed for a segment of Hungarian patients since May 2013. Between 2013 and February 2015, other direct acting antivirals and interferon-free combination therapies have been registered for the treatment of chronic hepatitis C with a potential efficacy over 90% and typically with a short duration of 8-12 weeks. Indication of therapy includes exclusion of contraindications to the drugs and demonstration of viral replication with consequent liver injury, i.e., inflammation and/or fibrosis in the liver. Non-invasive methods (elastography and biochemical methods) are accepted and preferred for staging liver damage (fibrosis). For initiation of treatment accurate and timely molecular biology tests are mandatory. Eligibility for treatment is a subject of individual central medical review. Due to budget limitations therapy is covered only for a proportion of patients by the National Health Insurance Fund. Priority is given to those with urgent need based on a Hungarian Priority Index system reflecting primarily the stage of liver disease, and considering also additional factors, i.e., activity and progression of liver disease, predictive factors of treatment and other special issues. Approved treatments are restricted to the most cost-effective combinations based on the cost per sustained viral response value in different patient categories with consensus between professional organizations, National Health Insurance Fund and patient organizations. More expensive therapies might be available upon co-financing by the patient or a third party. Interferon-free treatments and shorter therapy durations preferred as much as financially feasible. A separate budget is allocated to cover interferon-free treatments for the most-in-need interferon ineligible/intolerant patients, and for those who have no more interferon-based therapy option.

23 Guideline An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. 2015

Myers, Robert P / Shah, Hemant / Burak, Kelly W / Cooper, Curtis / Feld, Jordan J. · ·Can J Gastroenterol Hepatol · Pubmed #25585348.

ABSTRACT: Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last Canadian consensus conference on the management of chronic hepatitis C, major advances have occurred that warrant a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed and interferon-free, all-oral antiviral regimens have been approved. In light of this new evidence, an update to the 2012 Canadian Association for the Study of the Liver consensus guidelines on the management of hepatitis C was produced. The present document reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved antiviral agents, including those who have previously failed peginterferon and ribavirin-based therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.

24 Guideline American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. 2015

Reddy, K Rajender / Beavers, Kimberly L / Hammond, Sarah P / Lim, Joseph K / Falck-Ytter, Yngve T / Anonymous4600813. ·Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania. · Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina. · Division of Infectious Diseases, Brigham & Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. · Division of Gastroenterology and Hepatology, Yale University School of Medicine, New Haven, Connecticut. · Division of Gastroenterology and Hepatology, Department of Medicine, Case and VA Medical Center, Case Western Reserve University, Cleveland, Ohio. · ·Gastroenterology · Pubmed #25447850.

ABSTRACT: -- No abstract --

25 Guideline [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee]. 2014

Sarrazin, Christoph / Zeuzem, Stefan / Manns, Michael P / Anonymous2630819. · ·Z Gastroenterol · Pubmed #25621364.

ABSTRACT: -- No abstract --

Next